MENU
BIOA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BIOA stock forecast, quote, news & analysis

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging... Show more

BIOA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BIOA with price predictions
Jul 10, 2026

Momentum Indicator for BIOA turns positive, indicating new upward trend

BIOA saw its Momentum Indicator move above the 0 level on June 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator turned positive. In of the 34 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BIOA just turned positive on June 12, 2026. Looking at past instances where BIOA's MACD turned positive, the stock continued to rise in of 15 cases over the following month. The odds of a continued upward trend are .

BIOA moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BIOA crossed bullishly above the 50-day moving average on June 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in of 105 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 74 cases where BIOA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BIOA moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 23 cases where BIOA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

BIOA broke above its upper Bollinger Band on June 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (46.335). P/E Ratio (1.369) is within average values for comparable stocks, (99.034). BIOA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.679). BIOA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (79.365) is also within normal values, averaging (114.727).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIOA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.01B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 13%. TLPH experienced the highest price growth at 20%, while UPC experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 43%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
BIOA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of sustainable chemicals

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Chemicals Specialty
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Momentum Indicator for BIOA turns positive, indicating new upward trend